To include your compound in the COVID-19 Resource Center, submit it here.

Xgeva denosumab: Interim Phase II data

Interim data from an ongoing, open-label, international Phase II trial in 158 patients who received 120 mg subcutaneous denosumab every 4 weeks showed that 72 of 73 (99%) evaluable patients with surgically unsalvageable giant cell tumor of bone had

Read the full 398 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE